Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1205-1214

  Guan, Qingdong ^a,b   Blankstein, Anna R ^b   Anjos, Karla ^b   Synova, Oleksandra ^b   Tulloch, Marie ^b   Giftakis, Angeline ^b   Yang, Bin ^a   Lambert, Pascal ^b   Peng, Zhikang ^a   Cuvelier, Geoff D E ^a,b   Wall, Donna A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

Author keywords

Allogeneic hematopoietic stem cell transplant; Graft versus host disease; Immune regulatory cells; Myeloid derived suppressor cells; Recovery

Indexed keywords

ARGINASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; REGULATORY T LYMPHOCYTE; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; THROMBOCYTE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CELL COUNT; CELL LINEAGE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; GRAFT VS HOST DISEASE; GRANULOCYTE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MONOCYTE; PATHOLOGY; TIME FACTOR; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; B-LYMPHOCYTES; CELL COUNT; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; MYELOABLATIVE AGONISTS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84930590590     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.04.015     Document Type: Article

References (29)

1. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
2. Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 2009, 39:2670-2672.
3. Cripps J.G., Gorham J.D. MDSC in autoimmunity. Int Immunopharmacol 2011, 11:789-793.
4. Chou H., Hsieh C., Yang H., et al. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells. Hepatology 2011, 53:1007-1019.
5. Ochando J.C., Chen S.H. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012, 54:275-285.
6. Deshane J., Zmijewski J.W., Luther R., et al. Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness. Mucosal Immunol 2011, 4:503-518.
7. Guan Q., Moreno S., Qing G., et al. The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. JLeukoc Biol 2013, 94:803-811.
8. Marigo I., Bosio E., Solito S., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
9. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011, 32:19-25.
10. Mougiakakos D., Jitschin R., von Bahr L., et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013, 27:377-388.
11. Vendramin A., Gimondi S., Bermema A., et al. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Biol Blood Marrow Transplant 2014, 20:2049-2055.
12. Luyckx A., Schouppe E., Rutgeerts O., et al. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin Immunol 2012, 143:83-87.
13. Brudecki L., Ferguson D.A., McCall C.E., El Gazzar M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun 2012, 80:2026-2034.
14. Wang D., Yu Y., Haarberg K., et al. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant 2013, 19:692-702.
15. Highfill S.L., Rodriguez P.C., Zhou Q., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010, 116:5738-5747.
16. Zhou Z., French D.L., Ma G., et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010, 28:620-632.
17. Rieber N., Wecker I., Neri D., et al. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant 2014, 49:545-552.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
19. Laborde R.R., Lin Y., Gustafson M.P., et al. Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo/neg) cells): the gateway to improved responses. Front Immunol 2014, 5:147.
20. Dumitru C.A., Moses K., Trellakis S., et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012, 61:1155-1167.
21. Greten T.F., Manns M.P., Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011, 11:802-807.
22. Storek J., Dawson M.A., Storer B., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001, 97:3380-3389.
23. Storek J., Geddes M., Khan F., et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008, 30:425-437.
24. Juvet S.C., Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. JMol Cell Biol 2012, 4:48-58.
25. Lv M., Zhao X.S., Hu Y., et al. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. Am J Hematol 2015, 90:E9-E16.
26. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. JImmunol 2010, 185:2273-2284.
27. Blazar B.R., Murphy W.J., Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012, 12:443-458.
28. Visentainer J.E., Lieber S.R., Persoli L.B., et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003, 31:1044-1050.
29. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:935-940.